Q-Pharm Pty Limited
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
18.2%
2 terminated/withdrawn out of 11 trials
81.8%
-4.7% vs industry average
0%
0 trials in Phase 3/4
89%
8 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Role: collaborator
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Role: collaborator
MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants
Role: collaborator
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Role: collaborator
Experimental Falciparum Transmission to Anopheles
Role: collaborator
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
Role: collaborator
SJ733 Induced Blood Stage Malaria Challenge Study
Role: collaborator
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Role: collaborator
A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265
Role: collaborator
Safety and Blood Level Study of Unit Dose Budesonide
Role: collaborator
A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers
Role: collaborator
All 11 trials loaded